BCAP29

Across TCGA pan-cancer cohorts, BCAP29 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BCAP29 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BCAP29 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BCAP29 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where BCAP29 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.990	0.551	.001	18	view →
CCRCC	OS	Median	II,III,IV	0.082	1.000	.027	17	view →
GBM	DFS	Median	All	0.810	0.678	.015	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

BCAP29–PDAC (OS)

Open the PDAC breakdown →